Contribute Try STAT+ Today

WASHINGTON — The Food and Drug Administration is pushing drug companies to include younger people in drug trials for breast cancer drugs — a boon for the more than 16,000 American women under the age of 40 who are diagnosed with the condition each year.

The FDA’s new guidance, published in draft form earlier this month, encourages drug companies that are investigating hormonal treatments for breast cancer to include people who are premenopausal in the drug trials, provided they take adequate hormone-suppressing drugs. Until now, they had often been excluded from such studies, in part because drug companies worried their fluctuating hormones, which are different from those expressed by individuals who are post-menopausal, could affect the efficacy of the drug or even skew results.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.